VIDAS® NEPHROCHECK®
[TIMP-2 • IGFBP-7]
Know Sooner. Intervene Earlier. Avoid AKI.
VIDAS NEPHROCHECK identifies kidney stress before damage occurs, aiding in the risk assessment for moderate to severe acute kidney injury (AKI).1
- Image 3
- Image 4
- VIDAS NEPHROCHECK
- VIDAS NEPHROCHECK
What is Acute Kidney Injury?
AKI, previously referred to as acute renal failure (ARF), is an abrupt decrease in kidney function. It is a syndrome that is defined by a rapid increase in serum creatinine, decrease in urine output, or both. According to KDIGO (Kidney Disease: Improving Global Outcomes), there are 3 stages of AKI.2
Acute Kidney Injury Stages2
Note: Up to 50% of kidney function may be lost before any changes occur in SCr or UO.3,4
| Stage 1 | Stage 2 | Stage 3 |
Serum Creatinine (sCr) | Increase to ≥ 1.5 times baseline or Increase by ≥ 0.3 mg/dl (≥ 26.5 μmol/l) | 2.0–2.9 baseline
| 3.0 baseline, or increase to ≥ 4.0 mg/dl (≥ 353.6 μmol/l) within 48 hours; or initiation of renal replacement therapy |
Urine output (UO) | <0.5 ml/kg/h for 6 hours | <0.5 ml/kg/h for ≥ 12 hours | <0.3 ml/kg/h for ≥ 24 hours |
Causes and Clinical Impact of AKI
AKI is common among critically ill and post-cardiac-surgery patients, with many causes that include sepsis, nephrotoxic drugs, and circulatory shock.2,5-6
Here are some figures that summarize the clinical impact of AKI:
- Sepsis alone accounts for ~50% of AKI cases.7
- Up to 50% of critically ill patients develop AKI during hospitalization.8
- Hospital stay lengthens by 1–3 days.9
- Cardiac surgery patients with AKI are ~2-7x more likely to develop chronic kidney disease (CKD) at one year.10
Early identification enables timely protective measures and may prevent kidney failure.
VIDAS NEPHROCHECK
VIDAS NEPHROCHECK is a risk assessment that provides early insight into kidney stress before kidney damage occurs, supporting clinicians in ruling out AKI risk or initiating protective interventions.1 It runs on the VIDAS 3 immunoassay testing system.
The intended use of VIDAS NEPHROCHECK is in conjunction with clinical evaluation. It should be used in patients (21 years of age or older) who currently have or have had within the past 24 hours acute cardiovascular and/or respiratory compromise and are ICU patients as an aid in the risk assessment for moderate or severe AKI within 12 hours of patient assessment.
TIMP-2 and IGFBP-7
The assay detects TIMP-2 and IGFBP-7, two biomarkers associated with cell-cycle arrest, which indicates renal tubular stress.1 This allows for prompt intervention and prevention of AKI.
The Benefits of VIDAS NEPHROCHECK
Early Indicator
Elevates as early as four hours after ICU admission,12 which is days faster than SCr. | Specific to AKI
TIMP-2 and IGFBP-7 biomarkers rise only with AKI and are unaffected by common comorbidities, such as sepsis.11 | High Sensitivity
VIDAS NEPHROCHECK identifies up to 89.9% of patients who will develop AKI.13 |
How to Interpret VIDAS NEPHROCHECK Results
The concentration from each protein is converted into a single numerical result called the AKIRISK™ Score, which has an easy-to-interpret single cutoff.
VIDAS NEPHROCHECK Result | What it Means* |
Negative AKIRISK Score ≤ 0.30 | Patient is at lower risk of developing moderate to severe AKI within 12 hours of assessment |
Positive AKIRISK Score > 0.30 | Patient is at increased risk of developing moderate to severe AKI within 12 hours of assessment |
*Should not be used as a standalone test. Test results must be evaluated with other clinical laboratory test information. Refer to the VIDAS NEPHROCHECK Instructions for Use for full interpretation information.
Clinical Evidence for VIDAS NEPHROCHECK
There are numerous studies demonstrating that care guided by VIDAS NEPHROCHECK significantly reduces moderate-to-severe (Stage 2–3) AKI after cardiac surgery compared with routine post-operative care.14-16 For summaries of these studies, download the Acute Kidney Injury Literature Compendium below.
Technical Details
Number of tests per kit | 60 |
Sample type / prep | Urine sample – centrifuge 10 min at 1000 × g, +2 to +25 °C |
Contents of kit | 60 ready-to-use strips + 60 SPR devices, C1 Liquid Control (1.2 mL), S1 Liquid Calibrator (1.6 mL) |
Processing time | ~46 minutes |
Throughput | Up to 12 tests per run |
Sample stability (urine supernatant) | 5 hr room temp / 24 hr refrigerated / 6 mo frozen (2 freeze–thaw cycles) |
Quality control | Can be run day-of-use concurrently with patient tests |
Calibration | Each new lot or every 56 days |
LIS connection | Bidirectional |
System footprint | 24″ L × 29.5″ W × 25.2″ H |
Helpful Resources
- Kashani K, et al. Crit Care. 2013;17:R25.
- KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2012; 2:1-138.
- Ronco C, et al. Crit Care. (London, England) 2012;16:313-313.
- Sharma A, et al. Nephron Clin Pract. 2014;127:94-100.
- Kellum J, et al. Nat Rev Dis Primers 2021;7(1):52. doi: 10.1038/s41572-021-00284-z
- Nadim M, et al. Nat Rev Nephrol. 2020:16(12);747-64. doi.org/10.1038/s41581-020-00356-5
- Alobaidi R, et al. Semin Nephrol. 2015; 35(1):2-11.
- Mandelbaum T et al. Crit Care Med. 2011; 39(12):2659-2664.
- Dasta JF, et al. Nephrol Dial Transplant. 2008; 23(6):1970-1974.
- Legouis D, et al. Br J Anaesth. 2018;121(5):1025-1033
- Heung M, et al. Am J Kidney Dis. 2016; 67(5):742-752.
- Meersch M, et al. PLOS ONE. 2014;9:e93460
- VIDAS® NEPHROCHECK® Package Insert US. On file at bioMérieux.
- Engelman DT, et al. J Thorac Cardiovasc Surg. 2020;160:1235-1246.e2.
- Meersch M, et al. Intensive Care Med. 2017;43:1551-1561.
- Zarbock A, et al. Anesth Analg. 2021;133:292-302.
- VIDAS® 3 User Manual US Version. On file at bioMérieux.